ClearPoint Neuro (CLPT) Stock Statistics & Valuation Metrics

ClearPoint Neuro has a market cap or net worth of $561.40M. The enterprise value is $532.12M.

ClearPoint Neuro has 29,989,563 shares outstanding. The number of shares has decreased by -2.65% in one year.

ClearPoint Neuro’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -27.56%.

The current PE Ratio of ClearPoint Neuro is ―. ClearPoint Neuro’s PEG ratio is -0.53.

In the last 12 months, ClearPoint Neuro had revenue of 36.97M and earned -25.54M in profits. Earnings per share was -0.90.

In the last 12 months, operating cash flow was -25.72M and capital expenditures -984.00K, giving a free cash flow of -26.70M billion.

ClearPoint Neuro pays an annual dividend of ―, resulting in a dividend yield of ―

ClearPoint Neuro upcoming earnings date is Aug 11, 2026, After Close (Confirmed).

ClearPoint Neuro as a current ratio of 5.91, with Debt / Equity ratio of 337.50%

In the past 12 months, ClearPoint Neuro has paid 55.00K in taxes.

ClearPoint Neuro EV to EBITDA ratio is -19.16, with an EV/FCF ratio of -16.35.

ClearPoint Neuro has $35.59M in cash and marketable securities with $63.59M in debt, giving a net cash position of -$28.00M billion.

Gross margin is 61.82%, with operating margin of -65.36%, and net profit margin of -69.08%.

The average price target for ClearPoint Neuro is $28.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy